Monique J. Roobol
Erasmus University Medical Center
432 Papers
3K Citations
Monique J. Roobol is an academic researcher from Erasmus University Medical Center. The author has contributed to research in topics: Prostate cancer & Prostate-specific antigen. The author has an hindex of 64, co-authored 432 publications. Previous affiliations of Monique J. Roobol include Erasmus University Rotterdam.
Chat about Author
Papers
Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App
Nuno Pereira-Azevedo,Luís Osório,Avelino Fraga,Monique J. Roobol +3 more
- 06 Jan 2017
TL;DR: A smartphone app for prostate cancer screening, based on the Rotterdam Prostate Cancer Risk Calculator (RPCRC), which is helpful in predicting the risk of prostate cancer and, even more importantly, clinically significant prostate cancer.
50
Multiparametric Ultrasound for Prostate Cancer Detection and Localization: Correlation of B-mode, Shear Wave Elastography and Contrast Enhanced Ultrasound with Radical Prostatectomy Specimens
Christophe K. Mannaerts,Christophe K. Mannaerts,R.R. Wildeboer,Sebastiaan Remmers,Rob A. A. van Kollenburg,Amir Kajtazovic,Johanna Hagemann,Arnoud W. Postema,Ruud J. G. van Sloun,Monique J. Roobol,Derya Tilki,Massimo Mischi,Hessel Wijkstra,Hessel Wijkstra,Georg Salomon +14 more
TL;DR: In this article, the diagnostic performance of B-mode, shear wave elastography and contrast enhanced ultrasound with quantification software as well as the combination, multiparametric ultrasound, for clinically significant prostate cancer localization using radical prostatectomy histopathology as the reference standard was determined.
48
Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0–3.9 ng/ml)
André N. Vis,Robert F. Hoedemaeker,Monique J. Roobol,Theo H. van der Kwast,Fritz H. Schröder +4 more
TL;DR: The value of rectal examination as initial screening test for prostate cancer at low PSA values (0.0–3.9 ng/ml) was determined by evaluating the number and tumor characteristics of the cancers detected.
48
A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam).
TL;DR: The identification of predictors for prostate biopsy outcome at two screening rounds using a PSA ≥3.0 ng/ml as biopsy indication is identified.
45
Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients
Eva Hollemans,Esther I. Verhoef,Chris H. Bangma,John Rietbergen,Susanne Osanto,Rob C.M. Pelger,Tom van Wezel,Henk G. van der Poel,Elise Bekers,Jozien Helleman,Monique J. Roobol,Geert J.L.H. van Leenders +11 more
TL;DR: In multivariable analysis including age, prostate-specific antigen, pT-stage, surgical margin status, and lymph node metastases, presence of cribriform architecture was an independent parameter for biochemical recurrence-free and metastasis-free survival and has added value in risk stratification of Gleason score 8 prostate cancer patients.
44